TWD 31.25
(0.32%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 1 Billion TWD | -8.4% |
2022 | 1.1 Billion TWD | 117.44% |
2021 | 524.31 Million TWD | -24.86% |
2020 | 678.35 Million TWD | 269.09% |
2019 | 183.79 Million TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 293.41 Million TWD | 3.68% |
2024 Q1 | 286.01 Million TWD | 10.67% |
2023 Q4 | 263.47 Million TWD | 13.52% |
2023 FY | - TWD | -8.4% |
2023 Q3 | 232.09 Million TWD | -22.46% |
2023 Q2 | 299.33 Million TWD | 35.82% |
2023 Q1 | 220.38 Million TWD | -11.75% |
2022 FY | - TWD | 117.44% |
2022 Q4 | 249.72 Million TWD | 0.0% |
2021 FY | - TWD | -24.86% |
2020 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Allied Biotech Corporation | 204.79 Million TWD | -392.568% |
GeneFerm Biotechnology Co., Ltd. | 231.09 Million TWD | -336.506% |
Easywell Biomedicals, Inc. | -85.5 Million TWD | 1279.798% |
TTY Biopharm Company Limited | 1.52 Billion TWD | 33.827% |
Orient EuroPharma Co., Ltd. | 582.93 Million TWD | -73.044% |
Center Laboratories, Inc. | -175.17 Million TWD | 675.863% |
Tien Liang BioTech Co., Ltd. | 31.04 Million TWD | -3148.966% |
Orient Pharma Co., Ltd. | 172.39 Million TWD | -485.132% |
InnoPharmax Inc. | -62.12 Million TWD | 1723.855% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 126.67 Million TWD | -696.302% |
Excelsior Biopharma Inc. | -29.36 Million TWD | 3534.707% |
DV Biomed Co., Ltd. | 407.64 Million TWD | -147.458% |
Foresee Pharmaceuticals Co., Ltd. | -912.16 Million TWD | 210.588% |
Handa Pharmaceuticals, Inc. | 802.78 Million TWD | -25.655% |
UniPharma Co., Ltd. | -16.25 Million TWD | 6306.097% |
Anxo Pharmaceutical Co., Ltd. | 131.31 Million TWD | -668.212% |
Alar Pharmaceuticals Inc. | 394.52 Million TWD | -155.688% |
Winston Medical Supply Co., Ltd. | 228.32 Million TWD | -341.8% |
Mercury Biopharmaceutical Corporation | -39.03 Million TWD | 2684.257% |
Bioray Biotech Co., Ltd | 12.13 Million TWD | -8212.641% |
TSH Biopharm Corporation Limited | 99.35 Million TWD | -915.339% |